JAMA Publishes Positive Phase III Results for Sanbexin® Sublingual Stroke Treatment

A recent breakthrough in the treatment of acute ischemic stroke (AIS) has been reported in a Phase III clinical study. The study, known as TASTE-SL, was published in JAMA Neurology and highlighted the effectiveness of a new drug, Sanbexin® sublingual tablets. This medication, a collaborative effort between Simcere Pharmaceutical Group and Neurodawn Pharmaceutical Co., is a combination of edaravone and dexborneol designed for sublingual administration.

The innovative delivery method of Sanbexin® allows for the rapid dissolution of its active ingredients under the tongue, leading to swift absorption into the bloodstream. This approach is expected to offer a new avenue for stroke treatment, providing anti-inflammatory and free radical scavenging properties that can mitigate the damage caused by AIS and safeguard brain cells.

The TASTE-SL study, conducted across 33 research centers in China, involved 914 AIS patients who were administered the drug within 48 hours of the onset of their condition. The results were promising, showing a higher rate of good functional outcomes for patients who received Sanbexin® compared to those on a placebo. Specifically, 64.4% of the Sanbexin® group had a favorable outcome, as opposed to 54.7% in the placebo group, with an odds ratio of 1.50, indicating a statistically significant difference.

Furthermore, the study revealed that the benefits of Sanbexin® were consistent across various demographic and clinical factors, such as age, gender, and the presence of comorbidities like hypertension and diabetes. The drug also demonstrated a favorable safety profile, with similar rates of adverse events reported between the treatment and placebo groups.

Experts in the field have praised the findings, noting the potential for Sanbexin® to not only improve the recovery and independence of AIS patients but also to facilitate home treatment by offering a more convenient method of administration. The Phase III study has provided robust evidence supporting the use of Sanbexin® in clinical practice, marking a significant advancement in stroke care.